The U.S. Food and Drug Administration (FDA) had a busy week, marked by significant regulatory announcements, new enforcement actions, and noteworthy product approvals. From a crackdown on drug advertising to discussions about shifting away from traditional advisory committee meetings, the agency’s latest actions highlight its evolving approach to oversight in both drugs and medical devices.
HHS Unveils Childhood Health Strategy
On Tuesday, Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. released the Make American Healthy Again (MAHA) Commission report. The initiative aims to address the rise of chronic illnesses in children by targeting poor diet, chemical exposures, sedentary lifestyles, chronic stress, and overmedicalization.
The report also tasks FDA with several initiatives, including streamlining the use of certain investigational drugs in early trials and improving transparency in user fee negotiations.
FDA’s Crackdown on Drug Advertising
One of the most prominent developments this week was FDA’s announcement of a major effort to combat misleading prescription drug advertisements. The agency said it will end the long-standing “adequate provision” rule, which allowed companies to present a condensed risk statement in ads and direct consumers elsewhere for full labeling information.
FDA has already sent more than 100 cease-and-desist letters to drugmakers. Among them was AstraZeneca, which received an untitled letter over its Flumist television ad. The agency said the commercial’s fast-paced visuals and risk statement presentation made it difficult for viewers to absorb critical safety information.
Moving Away from Advisory Committees
George Tidmarsh, director of FDA’s Center for Drug Evaluation and Research (CDER), indicated this week that the agency wants to scale back its reliance on advisory committees to evaluate individual drugs. While he suggested that advisory panels may still convene for class-wide issues, Tidmarsh called the current approach redundant and burdensome for both FDA and sponsors.
This represents a notable shift in how the agency may weigh external expertise during the drug approval process.
Broader Health Policy Developments
Several other stories emerged from Washington this week:
- Vaccine Safety Debate: Reports indicate that health officials may present data linking child deaths reported in the Vaccine Adverse Event Reporting System (VAERS) to COVID-19 vaccines, despite CDC caution that VAERS is not designed to establish causality.
- Tylenol and Autism Claims: Media outlets reported potential claims about acetaminophen use in pregnancy and autism risk. While no official announcement has been made, Tylenol’s interim CEO reportedly met with Secretary Kennedy to argue against the alleged link.
- Accelerated Approvals: Experts in JAMA criticized FDA’s accelerated approval guidances as overly broad, recommending clearer expectations for confirmatory trials and postmarket monitoring.
New FDA Guidances
FDA issued and updated several guidances this week:
- A final guidance adopting the ICH E6(R3) Good Clinical Practice standards, designed to modernize clinical trial conduct.
- Reopening the comment period for ICH M13B guidance on bioequivalence for immediate-release solid oral dosage forms, open until October 9.
Product Approvals and MedTech News
The week also brought notable product approvals and industry news:
- AstraZeneca’s Koslugo: Expanded to treat children as young as one with NF1-related tumors.
- Takeda’s Vovendi: Approved for expanded use in von Willebrand disease.
- Johnson & Johnson’s Inlexzo: Approved for bladder cancer treatment.
- Travere’s Filspari: FDA waived advisory committee review for its sNDA, with a PDUFA date set for January 2026.
- Apple Watch Series 11: FDA cleared its new hypertension notification feature, broadening the role of consumer health devices.
- Upcoming Advisory Committee: FDA’s Digital Health Advisory Committee will meet in November to discuss generative AI in mental health devices.
Conclusion
This week’s updates reflect FDA’s evolving priorities, from advertising oversight and advisory committee practices to modernized guidances and groundbreaking product approvals. As regulators shift strategies and enforcement intensifies, life science companies must remain proactive in aligning with FDA’s expectations.
At EMMA International, we help sponsors navigate these changes by providing strategic regulatory support, compliance expertise, and quality system guidance. Whether preparing for FDA inspections, adapting to new guidance, or planning product approvals, our team ensures companies are positioned for success in a dynamic regulatory environment.
For more information on how EMMA International can assist, visit www.emmainternational.com. Contact EMMA International at (248) 987-4497 or by email at info@emmainternational.com to learn more.
